Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Lingua originale	English
pagine (da-a)	424-434
Numero di pagine	11
Rivista	American Journal of Respiratory and Critical Care Medicine
Volume	210
DOI	https://doi.org/10.1164/rccm.202403-0636oc
Stato di pubblicazione	Pubblicato - 2024

Keywords

@article{85da8571d6c54b9f99b8a9769976bd2f,

title = "Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial",

keywords = "IPF, safety, fibrotic disease, efficacy, IPF, safety, fibrotic disease, efficacy",

author = "Luca Richeldi",

year = "2024",

doi = "10.1164/rccm.202403-0636oc",

language = "English",

volume = "210",

pages = "424--434",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Lung Association:61 Broadway:New York, NY 10006:(212)315-8625, INTERNET: http://www.thoracic.org, Fax: (212)315-8613",

}

TY - JOUR

T1 - Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

AU - Richeldi, Luca

PY - 2024

Y1 - 2024

KW - IPF

KW - safety

KW - fibrotic disease

KW - efficacy

KW - IPF

KW - safety

KW - fibrotic disease

KW - efficacy

UR - http://hdl.handle.net/10807/289157

U2 - 10.1164/rccm.202403-0636oc

DO - 10.1164/rccm.202403-0636oc

M3 - Article

SN - 1073-449X

VL - 210

SP - 424

EP - 434

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

ER -